Cytos retrenches after its hypertension vaccine fails to show efficacy

Cytos Biotechnology AG said it will sharply reduce its headcount and development programs because its hypertension vaccine, CYT006-AngQb, failed to show a significant reduction in blood pressure in a Phase 2a trial.